retatrutide clinical trial results 2024 2025 press release Phase III study demonstrates 30% weight loss Summary of the highest percent

5 Together, SNAC-enabled peptide delivery and small-molecule agonists have the potential to expand access to incretin therapy by improving stability in the stomach, enhancing epithelial transport, and simplifying real-world use

It works across multiple areas of the face, such as the cheeks, chin, and forehead

Gut dysbiosis (an imbalance in the microbiome) has also been shown to lead to GLP-1 resistance, meaning your body doesnt properly respond to GLP-1 even when its released

It can be taken with food, although the manufacturer recommends it to be taken with meals to help maintain blood sugar levels

Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency

The earlier Phase 2 NEJM trial reported 24.2% average weight loss at 48 weeks